The ongoing Phase 3 DAYBREAK study in wet AMD explores in a definitive manner immediacy through the loading phase, real-world durability, and for KSI-501, the potential for better efficacy • Registrational study for both tarcocimab and KSI-501. Explores in a definitive manner immediacy through the loading phase, real-world durability, and for KSI-501, the potential for better efficacy Topline data: Q3 2026 Tarcocimab objective Assess 6-month durability potential with individualized Q4W to Q24W dosing KSI-501 objective Explore the efficacy potential of bispecific IL-6 and VEGF inhibition in fixed Q8W dosing with additional individualized monthly dosing Noninferiority study 6-month durability (tarcocimab) Better efficacy (KSI-501) Wet AMD DAYBREAK • Uses an AI-based tool to precisely measure fluid in the eye so treatment is optimized per patient • In high-need patients treats until dry, enables monthly dosing and detects disease reactivation earlier • In long-durability patients allows patients without active disease to safely go to every 6-month dosing 36 Quadrant of core unmet need